The Determination of Blood-Brain Barrier Permeability and Pharmacokinetics of a Rat Transferrin Receptor Monoclonal Antibody by Brain Perfusion Method and Intravenous Injection Technique in Mice

마우스에서 뇌관류법과 정맥투여법에 의하여 흰쥐 트란스페린 단일항체의 체내동태 및 혈액-뇌 관문 투과성의 검토

  • 강영숙 (숙명여자대학교 약학대학)
  • Published : 2002.03.01


Brain drug targeting through the blood-brain barrier (BBB) in vivo is possible with peptidornirnetic monoclonal antibodies that undergo receptor-mediated transcytosis through the BBB. Monoclonal antibody to the rat transferrin receptor, such as the OX26 was studied in rats as a transport vector through BBB on the transferrin receptor. But, OX26 is not an effective brain delivery vector in mouse. In the present studies, rat monoclonal antibody, 8D3 to the mouse transferrin receptor were evaluated for brain drug targeting vector intransgenic mouse model. Pharrnacokinetic parameters in plasma and organ uptakes were determined at varioustimes after i.v. bolus injection of [$^{}125}I$] 8D3 in Balb/c mice. Brain uptake of [$^{}125}I$] 8D3 was also studied with an internal carotid artery perfusioncapillary depletion method. After i.v. injection of [$^{}125}I$] 8D3, plasma concentrations declined biexponentially with elimination half lift of approximately 2.2 hours. Brain uptake of [$^{}125}I$] 8D3 was $0.50{\pm}0.09$ persent of injected dose per g brain after 2 hours i.v. injection. After perfusion 5 min the apparent volume of distibution of [$^{}125}I$] 8D3 in brain was $22.3 {\mu}l/g,$ which was 4.8 fold higher than the intravascular volume. These studies indicate rat monoclonal antibody to the mouse transferrin receptor, 8D3 may be used for brain drug targeting vector in mice.



  1. Bickel, U., Yoshikawa, T. and Pardridge, W. M. (1993). Deliveiy of peptides and proteins through the blood-brain barrier. Adv. Drug DeIivery Rev., 10, 205-245
  2. Gibaldi, M. and Perrier, D. (1982). Pharmacokinetics, pp. 1- 329. Marcel Dekker Inc., New York
  3. Jaenisch, R. (1988). Transgenic animals. Science, 240, 1468-1474
  4. Jeffferries, W. A., Brandon, M. R., Williams, A. F. and Hunt, V. (1985). Analysis of lymphopoietic stem cells with a monoclonal antibody to the transferrin receptor. Im-munology, 54, 333-341
  5. Kang, Y.S. (1997). Vector-mediated delivcry of $^{125}I$-labeled opioid peplide, [Lys7]dermorphin (K7DA), thhrough the blood-brain barrier. J. Appl. Pharmacol., 5, 53-58
  6. Kang, Y. S., Boado, R. J. and Pardridgc, W. M. (1995). Phar-macokinetics and organ clearance of a 3'-biotiny1ated, internally [$^{32}P$]-labeled phosphodiestcr oligodeoxynucieo-tide coupled to a neutral avidin/monoclonal antibody conjugate. Drug Metabol. Dispos., 23, 1, 55-59
  7. Kang, Y. S. and Kim, J. M. (1999). Permeability of a capsaicin derivative, [$^{14}C$]DA-5018 to blood-brain barrier coirected with HPLC method. Arch. Pharm. Res., 22, 2, 99-105
  8. Kang, Y. S. and Kim, Y. J. (2000). The simple in vivo cvaluation method for blood-brain barrier permeability of drugs in mice. J. Kor. Pharm. Sci., 30, 99-105
  9. Kang, Y. S. and Pardridge, W. M. (1994). Use of neutral avidin improves phamiacokmetics and brain delivery of biotin bound to an avidin-monoclonal antibpdy conjugate. J. Pharm. Exp. Ther., 269, 344-350
  10. Kissel, K., Hamm, S., Schulz, M., Vecchi, A., Garlanda, C. and Engelhardt, B. (1998). Immunohistochemical 10caliza-tion of the murine transferrin receptor (TfR.) on blood-tissue barriers using a novel anti-TfR monoclonal antibody. His-tochem. Cell Biol., 110, 63-72
  11. Lee, H. J., Engelhardt, B., Lesley, J., Bickel, U. and Pardndge, W.M. (2000). Targeting rat anti-mousc transferrin receptor monoclonal antibodies through the blood-brain barrier in mouse. J. Pharm. Exp. Ther., 292, 1048-1052
  12. Pardridge, W. M., Boado, R. J. and Kang, Y. S. (1995a). Vector-mediated delivery of a polyamide ('peptide') nucleic acid analogue through the blood-brain barrier invivo. Proc. Natl. Acad. Sci. USA, 92, 5592-5596
  13. Pardridge, W. M., Kang, Y. S., Yang, J. and Buciak, J. L. (1995b). Enhanced cellular uptake and and in vivo biodistribulion of a monoclonal antibody following cationi-zation.J. Pharm. Sci., 84, 943-948
  14. Pardridge, W. M., Buciak, J. L., Friden, P. M. (1991). Selective transport of anti-transferin rcceptor antibody through the blood-brain barrier in vivo. J. Pharm. Exp. Ther., 259, 66.70
  15. Pardridge, W. M., Kang, Y. S., Diagne, A. and Zack, J. A. (1996). Cationized hypehimnune immunoglobulms: Phar-macokinetics, toxicity evaluation and treatmcnt of human immunodeficiency virus-infected human-peripheral blood lymphocytes-sevcre combined immune deficiency mice.J. Pharm. Exp. Ther., 276, 246-252
  16. Pardridge, W. M., Kang, Y. S. and Buciak, J. L. (1994). Transport of human recombinant, brain-dcrived neurotrophic factor (BDNF) through the rat blood-brain barrier in vivo using vector-mediated peptide drug delivery. Pharm. Res., 11, 5, 738-746
  17. Pardridge, W. M., Kang, Y. S., Buciak, J. L. and Yang, J. (1995). Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. Pharm. Res.., 12, 6, 807-816
  18. Pardridge, W. M.. Kang, Y. S., Yang, J. and Buciak, J. L. (1995). Enhaiiced cellular uptake and in vivo biodistribution of anti-ras monoclonal anlibody following cationization. J. Pharm. Sci., 84, 8, 943-948
  19. Smith, Q. R. (1996). Brain perfusion system for studies of drug uptake and metabolism in thc central nervous system: In Models for assessing drug absorption and mctabolism, Plenum Press, New York, pp. 285-307
  20. Takasato, Y, Rapoport, S. I. and Smith, Q. R. (1984). An in situ brain perfusion technique to sludy cerebrovascular transport in the rat. Am. J. Phvsiol., 247, H484-493
  21. Triguero, D., Buciak, J. B. and Pardridge, W. M. (1990). Capillary depletion method for quantifying blood-brain barrier transcytosis of circulating peptides and plasma proteins. J. Neurochem., 54, 1882-1888
  22. Wu, D., Yang, J. and Pardridge, W. M. (1997). Drug targeting of a peptide radiopharmaceutical through the primate b100d-brain barrier in vivo with a monoclonal antibody to the human insulin reccptor. J. CIin. Invest., 100, 1804-1812